Blood Cancers

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

The FDA announced several regulatory actions the past few weeks.

Early referral to transplantation can increase access to transplant and cell therapies, as well as improve outcomes among patients with hematologic malignancies, according to a speaker at Chemotherapy Foundation Symposium.

The FDA granted priority review to omidubicel, an investigational donor-based stem cell therapy for patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation.

Frailty assessments are important predictors of future health outcomes among geriatric patients with hematologic malignancies.

Firefighters and EMS providers with low levels of serum IgE who responded to the attack on the World Trade Center on and after Sept. 11, 2001, had significantly higher odds for developing a hematologic malignancy, a recent study reported.

Less than half of patients with hematologic malignances exhibited seroconversion after receiving their initial COVID-19 vaccine, research published in Cancer showed.

The addition of tranexamic acid prophylaxis to platelet transfusion did not reduce bleeding among patients with blood cancers and severe thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.